Press "Enter" to skip to content

‘Like a Delirium Factory’: What We Heard This Week

“What we’re learning is that COVID in the ICU is like a delirium factory.” — Wes Ely, MD, of Vanderbilt University Medical Center in Nashville, on how acute brain dysfunction occurred frequently and was prolonged in critically ill COVID-19 patients.

“This is the right thing to do. To say ‘no’ was not an option.” — Thomas Cavalieri, DO, dean of Rowan University School of Osteopathic Medicine in Stratford, New Jersey, where students are helping co-run a COVID-19 vaccination site.

“Those are time and financial resources that could be put to better use elsewhere.” — Ariel Levin, senior associate director for policy at the American Hospital Association, on a new federal transparency rule requiring hospitals to post prices insurers pay for services.

“This is a major step forward showing that blood tests for tau pathology and neurodegeneration have clinical value to track disease progression in patients with Alzheimer’s disease.” — Kaj Blennow, MD, PhD, of University of Gothenburg in Sweden, discussing blood-based biomarkers that paralleled cognitive impairment and Alzheimer’s brain changes over time.

“Certainly, it’s not the steep decline that we would hope our efforts have contributed to at this point.” — Courtney Townsel, MD, MSc, of University of Michigan in Ann Arbor, on increasing rates of maternal opioid disorders and neonatal abstinence syndrome.

“Hormone therapy is not as unsafe as the general community and the greater medical community has feared it to be.” — John Pang, MD, of the Mount Sinai Center for Transgender Medicine and Surgery in New York City, discussing risk of perioperative venous thromboembolism in transgender patients undergoing gender-affirming surgery.

Source: MedicalNewsToday.com